Renal cell carcinoma is not the only type of kidney cancer, although it does account for 9 out of 10 cases. About 5% of kidney cancer patients have transitional cell or urothelial carcinoma, which start at the point where the ureters meet the kidneys, the lining of the renal pelvis.
Renal Cell Carcinoma Continues to Rise Worldwide; More Common in Veterans
Kidney cases continue to rise nationwide, with more than 81,600 individuals expected to be diagnosed with the disease by year-end, the American Cancer Society estimates.
Selecting First-Line Therapy in Advanced Renal Cell Carcinoma
The rapid expansion of treatment options for advanced or metastatic renal cell carcinoma (RCC) in the last decade has improved survival rates and brought hope to the one-third of RCC patients diagnosed with Stage IV cancer.
New Guidelines Make Targeted Therapy Recommendations for CRC
The American Society of Clinical Oncology (ASCO) recently developed recommendations for the treatment of patients with metastatic colorectal cancer (mCRC).
More Research Needed on MMPs, Especially in CRC Patients With IBD
An important research focus in colorectal cancer concerns the enzymes comprising the 24-member matrix metalloproteinase (MMP) family of zinc- and calcium-dependent endopeptidases.
Understanding of KRAS Variations and Their Management Is Evolving
Since 2010, KRAS molecular testing has been guideline-recommended in the VA healthcare system. The goal has been to help determine how metastatic cancer is likely to respond to anti-EGFR drug therapy.
VA Pushes to Increase Uptake of Genomic, Other Precision-Testing in CRC
Patients receiving oncology care within a VHA facility are eligible for genomic- and other precision-testing, if they have an advanced-stage tumor or blood cancer and can tolerate recommended therapies.
Epidemiological Changes in CRC Will Have Significant Impact on VHA
The VA treats about 3% of all cases of colorectal cancer (CRC) in the United States each year—6% among cases in men. So, any epidemiological changes have an outsized effect on the nation’s largest integrated healthcare system.
More Diverse Dataset Raises Questions about MGUS Risk Models
Patients with monoclonal gammopathy of undetermined significance (MGUS) have been thought to have a less than 1% chance of progressing to multiple myeloma as long as their M-protein levels are below 1.5 g/dL.
Lower Relapse Rates Suggest Limited Value for Prophylaxis in DLBCL
Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) relapse or progress following first-line chemoimmunotherapy.
For CLL, BTK Inhibitors Appear to Extend Time to Next Line Most
JACKSONVILLE, FL—As treatment options for chronic lymphocytic leukemia (CLL) multiply, physicians face an increasing array of sequencing options but have little guidance from clinical trials of the most effective order given each patient’s specific disease...
MGUS Higher in Servicemembers, No Association Seen With Burn Pit Exposure
Individuals who have served in the U.S. military have about three times the risk of monoclonal gammopathy of undetermined significance (MGUS) as a similarly aged cohort in the Icelandic iStopMM study.
Mental Health Issues Increase Mortality in Some Veterans With AML
Venetoclax combinations are common treatments for individuals with acute myeloid leukemia (AML) who are unable to withstand the rigors of intensive induction chemotherapy.
BTK Inhibitors Provide Option for CLL Patients With Severe Renal Dysfunction
BTK inhibitors have proven to be a powerful tool in CLL treatment and have replaced chemoimmunotherapy as the preferred first-line treatment.
Evaluate Veterans With MGUS for Cardiovascular Disease
Monoclonal gammopathy of undetermined significance (MGUS) is not considered a hematological condition of concern, yet it is associated with lower overall survival. VA researchers led by Lawrence Liu, MD, of the St. Louis VAMC, explored whether the reduced life expectancy arose from an increased risk of cardiovascular events.
Dasatinib Fails to Improve Outcomes in B-ALL With ABL-Class Fusions
While most blood cancers affect people in their later years, B-cell acute lymphoblastic leukemia (B-ALL) strikes at a much earlier age. It is the most common hematologic malignancy in adults under the age of 40, the age range of 80% of U.S. servicemembers.
Deployment Linked to Longer Survival in Servicemembers, Veterans With NHL
A study presented at the 2023 ASH Conference, provided additional evidence for the healthy deployer effect, this time in individuals with non-Hodkin lymphoma.
Which Veterans Should Undergo SPEP Testing for Plasma Cell Dyscrasia?
Plasma cell dyscrasia affects up to 5% of adults. While often asymptomatic, its characteristic clonal expansion of bone marrow plasma cells can also indicate the presence of several hematological malignancies including multiple myeloma.
GLP-1 Use Reduces Risk of MGUS Progression in Some Veterans
Glucagon-like peptide 1 (GLP-1) receptor agonists have gained huge popularity as they have demonstrated the ability to substantially reduce both blood-glucose levels and weight. In addition, recent research suggests cardiovascular and renal benefits to their use in certain populations.
Agent Orange Increases CVD Risk in Veterans With Myeloproliferative Neoplasms
As Vietnam-era veterans move into the age range in which most myeloproliferative neoplasms (MPNs) develop, the VA has a keen interest in fully understanding the full impact of exposure to Agent Orange in veterans with these malignancies.
Clinicians Puzzled by Sharp Rise in Colorectal Cancer Patients Younger Than 50
Colorectal cancer (CRC) is the third-most-common cancer globally and ranks second as the most-common cause of cancer-related mortality.
Primary Tumor Sidedness Increasingly Important in CRC Diagnosis, Treatment
In colorectal cancer, left-sided colorectal cancer (LCC) is associated with better survival compared to right-sided colon cancer (RCC) in metastatic disease, according to a study involving VA researchers.
Tumor Location Increasingly Important for Determining Optimal CRC Treatments
Traditionally, treatment for colon cancer has been based primarily on the stage, but other issues—especially location—are becoming increasingly important.
VA Participated in Research Examining Major, Minor Colonoscopy Risks
Colonoscopies are not without risk, yet data are limited regarding the procedures’ long-term adverse effects.
Colorectal Cancer Screening Has Changed Significantly in Recent Years
In recent years, the protocols for colorectal cancer screening have undergone some significant changes.